glp-1/gip agonists GLP-1 Receptor – Peripheral Brain New strategies for the treatment

The researchers of that study called for urgent clarification of drug- and patient-related risk factors, an understanding that has become more important as GLP-1 receptor agonist use continues to rise across the United States, especially for weight management

Lillys Oral GLP-1, Orforglipron, Delivers Weight Loss of Up to an Average of 27.3 Lbs in First of Two Pivotal Phase 3 Trials in Adults With Obesity

Symptoms include shaking, sweating, dizziness, and confusion

Cardiol Res Pract 2021:111

When combined with the exclusion of patients with either acute or chronic pancreatitis from prior clinical trials, this observation aligns with the caution raised by the American Diabetes Association to avoid use of GLP-1RAs for patients with any history of acute or chronic pancreatitis 27

A.AguilaM